I want to thank the authors and experts for the thoughtful and enlightening discussion so far. It appears that based on the collected evidence and FOURIER, a main goal for treating patients at high risk for ASCVD is to lower LDL-C by some combination of statins, ezetimibe, and PCSK9 inhibitors. For the practicing internists who have the rare statin intolerant patients that failed multiple trials of different statins, can they be reassured that monotherapy with a PCSK9 inhibitor that lowers LDL-C to a goal range is sufficient? Should they still try to get their patients on a minimally tolerated dose of statin, such as with an alternating day regimen? For primary prevention patients, is evolocumab a substitute for a "high" intensity statin under current guidelines? Of course, cost and insurance coverage factor in the equation, so let's consider this mainly from an outcomes perspective.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.